Company Bio-Rad Laboratories, Inc.
Equities
BIO
US0905722072
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
345.9 USD | -1.06% | -1.74% | +7.12% |
Mar. 25 | Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center | MT |
Mar. 20 | Bio-Rad Laboratories Appoints Roop Lakkaraju as CFO | MT |
Business Summary
- manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems;
- manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets;
- other (0.1%): in particular, manufacturing of analytical instruments.
At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore.
Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).
Number of employees: 8,030
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Clinical Diagnostics
55.8
%
| 1,451 | 51.8 % | 1,489 | 55.8 % | +2.64% |
Life Science
44.1
%
| 1,347 | 48.1 % | 1,178 | 44.1 % | -12.53% |
Other
0.1
%
| 4 | 0.1 % | 4 | 0.1 % | -10.00% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
42.0
%
| 1,156 | 41.2 % | 1,122 | 42.0 % | -2.91% |
Europe
30.7
%
| 852 | 30.4 % | 820 | 30.7 % | -3.77% |
Asia
21.1
%
| 639 | 22.8 % | 563 | 21.1 % | -11.95% |
Other (Primarily Canada and Latin America)
6.2
%
| 155 | 5.5 % | 167 | 6.2 % | +7.21% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Norman Schwartz
CEO | Chief Executive Officer | 74 | 88-12-31 |
Gregory Hinckley
DFI | Director of Finance/CFO | 77 | 83-01-31 |
Andrew Last
COO | Chief Operating Officer | 64 | 19-04-21 |
Allison Schwartz
BRD | Director/Board Member | 43 | 15-12-31 |
Edward Chung
IRC | Investor Relations Contact | - | - |
Andrew Stapleton
PRN | Corporate Officer/Principal | 68 | - |
Jonathan Seaton
PRN | Corporate Officer/Principal | 53 | - |
Michael Crowley
PRN | Corporate Officer/Principal | 62 | 97-12-31 |
Timothy Ernst
LAW | General Counsel | 64 | 16-05-31 |
Simon May
PRN | Corporate Officer/Principal | - | 13-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Edwards
BRD | Director/Board Member | 64 | 17-04-24 |
Alice Schwartz
FOU | Founder | 97 | 51-12-31 |
Gregory Hinckley
BRD | Director/Board Member | 77 | 17-04-24 |
Norman Schwartz
CEO | Chief Executive Officer | 74 | 88-12-31 |
Director/Board Member | 65 | 17-04-24 | |
Director/Board Member | 66 | 17-04-24 | |
Allison Schwartz
BRD | Director/Board Member | 43 | 15-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,095,930 | 124,454 ( 2.442 %) | 0 | 66.01 % |
Stock B | 0 | 25,169,944 | 19,853,630 ( 78.88 %) | 1,747,438 ( 6.943 %) |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
SARTORIUS AG 34.69% | 12,987,900 | 34.69% | 3,879,140,252 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Bio-Rad Laboratories GmbH
Bio-Rad Laboratories GmbH Pharmaceuticals: MajorHealth Technology Bio-Rad Laboratories GmbH engages in the development and production of analytical instruments and products for life science research, food/animal/environment testing, and clinical diagnostics. The company is headquartered in Munich, Germany. |
Pharmaceuticals: Major
|
Bio-Rad Laboratories MEPE
|
Sector
Sales per Business
Sales per region
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.12% | 9.79B | |
+3.26% | 197B | |
+5.79% | 116B | |
+1.48% | 71.49B | |
+11.77% | 53.47B | |
+18.31% | 48.42B | |
+6.33% | 43.64B | |
+12.38% | 28.97B | |
+9.76% | 28.47B | |
+10.35% | 27.78B |
- Stock
- Equities
- Stock Bio-Rad Laboratories, Inc. - Nyse
- Company Bio-Rad Laboratories, Inc.